

Pharmacy



Prior Authorization Criteria for: Zelboraf (vermurafenib)

Background

Vermurafenib (Zelboraf) is an oral kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAFv600E mutation. Zelboraf is not recommended for use in wild-type BRAF melanoma. The FDA also approved a new molecular diagnostic test (Cobas 4800) designed to detect the BRAFv600E mutation and identify patients likely to respond to Zelboraf therapy.

The following criteria apply to prescriptions for vermurafenib obtained through the TRICARE Mail Order or retail network pharmacies as part of the TRICARE Program (TPHARM). The prior authorization form for vermurafenib is available on the TRICARE Pharmacy Prior Authorization page.

Effective Date - 6 June 2012

Prior Authorization Criteria for Zelboraf (vermurafenib)

- Coverage will be approved for the treatment of patients with documented diagnosis of unresectable or metastatic melanoma with BRAFv600E mutation, detected by a FDAapproved test such as Cobas 4800.
- Coverage will not be approved for patients with wild-type BRAF melanoma.

www.tricare.mil is the official Web site of the TRICARE Management Activity, a component of the Military Health System Skyline 5, Suite 810, 5111 Leesburg Pike, Falls Church, VA 22041-3206



Prior Authorization Request Form for Zelboraf (vemurafenib)



5673

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) TRICARE pharmacy program (TPHARM). Express Scripts is the TPHARM contractor for DoD.

MAIL ORDER and RETAIL The provider may call: 1-866-684-4488 or the completed form may be faxed to: 1-866-684-4477

The patient may attach the completed form to the prescription and mail it to: Express Scripts, P.O. Box 52150, Phoenix, AZ 85072-9954 or email the form only to:
 TPharmPA@express-scripts.com

Prior authorization criteria and a copy of this form are available at: http://pec.ha.osd.mil/forms_criteria.php. This prior authorization has no expiration date.

Step	Please complete patient and physician information (please print):			
1	Patient Name: F		ysician Name:	
	Address:		Address:	
	Sponsor ID # Date of Birth:		Phone #: Secure Fax #:	
Step	Please complete the clinical assessment:			
2	Does the patient have a documented diagnosis of		☐ Yes	□ No
	unresectable or metastatic melanoma with BRAF ^{V600E} mutation that has been detected by an FDA-approved test such as Cobas 4800?		Proceed to Question 2	STOP Coverage not approved
	2. Does the patient	have a wild-type BRAF melanoma?	☐ Yes	□ No
			STOP Coverage not approved	Sign and date below
Step 3	I certify the above is true to the best of my knowledge. Please sign and date:			
	Р	rescriber Signature	Date	
				[6 June 2012]

[6 June 2012]